ATLANTA, GA – – (Globe Newswire – January 27, 2025) – – A shareholder class action lawsuit has been filed against ESSA Pharma Inc. (“ESSA” or the “Company”) (NASDAQ: EPIX). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information regarding the Company’s business, operations, and prospects, including allegations that: (i) masofaniten in combination with enzalutamide had no clear efficacy benefit over enzalutamide alone; (ii) accordingly, masofaniten in combination with enzalutamide was less effective in treating prostate cancer than Defendants had led investors to believe; (iii) the M-E Combination Study was unlikely to meet its prespecified Phase 2 primary endpoint; and (iv) accordingly, Defendants had overstated masofaniten’s clinical, regulatory, and commercial prospects.

If you bought shares of ESSA between December 12, 2023 and October 31, 2024, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com/case/essa-pharma/ to learn more.

The deadline to ask the court to be appointed lead plaintiff in the case is March 25, 2025.